Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 252.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 46,967 shares of the company’s stock after purchasing an additional 33,651 shares during the period. SG Americas Securities LLC’s holdings in Allogene Therapeutics were worth $132,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ALLO. Bourgeon Capital Management LLC raised its holdings in shares of Allogene Therapeutics by 12.8% in the first quarter. Bourgeon Capital Management LLC now owns 57,200 shares of the company’s stock valued at $256,000 after buying an additional 6,500 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its position in Allogene Therapeutics by 85.1% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock valued at $79,000 after acquiring an additional 8,162 shares during the period. Nisa Investment Advisors LLC raised its stake in Allogene Therapeutics by 429.6% during the 2nd quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after acquiring an additional 8,734 shares during the last quarter. Arizona State Retirement System lifted its position in Allogene Therapeutics by 36.1% during the 2nd quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock worth $95,000 after acquiring an additional 10,855 shares during the period. Finally, Federated Hermes Inc. acquired a new stake in Allogene Therapeutics during the 2nd quarter worth approximately $29,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Stock Down 3.9 %

Shares of NASDAQ ALLO opened at $2.44 on Friday. The stock has a market capitalization of $509.96 million, a price-to-earnings ratio of -1.36 and a beta of 0.83. Allogene Therapeutics, Inc. has a 52 week low of $2.01 and a 52 week high of $5.78. The firm has a 50-day moving average price of $2.69 and a 200 day moving average price of $2.72.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. Equities research analysts expect that Allogene Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Citigroup upped their price target on Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a research report on Thursday, August 15th. Oppenheimer initiated coverage on shares of Allogene Therapeutics in a research note on Thursday, August 8th. They issued an “outperform” rating and a $11.00 target price for the company. Canaccord Genuity Group dropped their price target on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Finally, Truist Financial reissued a “buy” rating and set a $14.00 price target (down from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.96.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).